Redwood Bioscience Inc., of Burlingame, Calif., secured an undisclosed amount of funding from Takeda Ventures Inc. to further develop its precision protein-chemical engineering platform for drug conjugate optimization. The money will advance Redwood's site-specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.